Next-Generation Sequencing Platforms
Comparing Illumina, Element AVITI, PacBio, and Oxford Nanopore to find the perfect match for your project.
Introduction
Next-Generation Sequencing (NGS) technology has evolved rapidly. At Yaazh Xenomics, we operate and provide services across the major NGS platforms — Illumina, Element Biosciences AVITI, Oxford Nanopore Technologies (ONT), and PacBio — so we can recommend and execute the optimal platform for your specific scientific question, sample type, budget, and turnaround requirements.
This technical guide compares all four platforms with accurate 2026 specifications, advantages, limitations, ideal applications, and a clear decision framework for choosing the right NGS platform.
How to Choose the Right NGS Platform
Step 1
What is your primary goal?:• Highest throughput + lowest cost per Gb + clinical validation needed → Illumina • Best accuracy + competitive cost for short-read projects → AVITI • Highest accuracy long reads for SVs, repeats, de novo → PacBio HiFi • Ultra-long reads + real-time + methylation + rapid turnaround → Oxford Nanopore
Step 2
Do you need long reads?:• No (or only for small SVs) → Short-read (Illumina or AVITI) • Yes (structural variants, repeats, de novo, isoforms) → Long-read (PacBio or Nanopore)
Step 3
Accuracy vs Length Priority:• Maximum accuracy long reads → PacBio HiFi • Maximum read length + real-time + epigenetics → Nanopore
Step 4
Project Scale & Budget:• Very large cohorts or population studies → Illumina (or AVITI for cost) • Moderate scale with need for long reads → PacBio or Nanopore (or hybrid)
Step 5
Special Requirements:• Methylation / epigenetics without conversion → Nanopore (or PacBio) • Real-time results (outbreak, clinical rapid) → Nanopore • Full-length transcripts → PacBio Iso-Seq or Nanopore cDNA/direct RNA
Hybrid Approaches (Recommended for Many Projects)
Many leading projects now combine platforms: • Illumina high-coverage short reads + Nanopore/PacBio long reads for superior assemblies and SV calling. • Yaazh Xenomics routinely designs and executes hybrid NGS strategies.
Detailed Platform Breakdown
Understanding the strengths, limitations, and best applications for each technology.
1. Illumina Platforms
Most widely used short-read technology in the world. Key Strengths: • Extremely high accuracy and mature bioinformatics ecosystem (GATK, DRAGEN, etc.). • Highest throughput and lowest cost per Gb for large-scale projects (WGS, WES, RNA-Seq, metagenomics). • Gold standard for clinical diagnostics and population-scale studies. • Excellent for high-depth targeted sequencing and amplicon work. Limitations: • Short reads struggle with structural variants, long repeats, pseudogenes, and complex genomic regions. • De novo assembly is more fragmented compared to long-read platforms. Best Applications at Yaazh Xenomics: • Clinical Exome / Whole Genome Sequencing (high depth) • Large cohort WGS / population genomics • RNA-Seq (gene expression, differential analysis) • Metagenomics (shotgun & 16S/18S) • High-throughput targeted panels
2. Element Biosciences AVITI Sequencer
A newer short-read platform gaining strong traction in 2025–2026 for its accuracy and cost profile. Key Strengths: • Very high base-calling accuracy (frequently marketed with Q40-level performance). • Competitive or better cost per Gb than Illumina in mid-to-high throughput ranges. • Flexible throughput and good data quality for both research and emerging clinical use. • Lower instrument and consumable costs in many configurations. Limitations: • Still building the same level of global validation and clinical adoption as Illumina. • Bioinformatics ecosystem is smaller but rapidly growing. Best Applications: • High-accuracy short-read WGS/WES where cost optimization is important • Large RNA-Seq or metagenomics projects • Projects needing very low error rates for variant calling
3. PacBio (HiFi Long-Read Sequencing)
Best-in-class accuracy for long reads. Key Strengths: • HiFi reads deliver >99.9% accuracy while maintaining long read lengths (10–20 kb typical). • Outstanding performance for structural variants, repeat expansions, and complex regions. • Excellent de novo genome assembly and haplotype phasing. • Good for full-length transcript isoform sequencing (Iso-Seq). • Native detection of some epigenetic modifications. Limitations: • Higher cost per Gb than short-read platforms for very large projects. • Library preparation can require higher quality DNA and more careful handling. Best Applications: • De novo genome assembly (human, plant, animal, microbial) • Structural variant discovery in rare disease and cancer • Complex repeat disorders • Full-length RNA isoform sequencing • High-quality reference genome generation
4. Oxford Nanopore Technologies
Leader in ultra-long read and real-time sequencing. Key Strengths: • Ultra-long reads (N50 often 20–50 kb+, reads >1 Mb possible) — unmatched for spanning repeats and complex SVs. • Real-time sequencing and base calling (results available during the run). • Direct native DNA/RNA sequencing — detects methylation and other modifications without bisulfite conversion. • Highly portable options (MinION/Flongle) for field or rapid outbreak work. • Improving raw accuracy with latest R10 chemistry and duplex methods. Limitations: • Raw read accuracy still lower than PacBio HiFi or short-read platforms (though consensus accuracy is now excellent). • Higher computational requirements for base calling on very large runs. Best Applications: • Structural variant and repeat expansion detection • Rapid pathogen identification and outbreak tracking • Metagenomics (full-length 16S/18S + shotgun) • De novo assembly (especially hybrid with Illumina) • Epigenetics / methylation profiling • Full-length cDNA / direct RNA sequencing • Low-input or precious samples
Side-by-side technical parameters across the four major sequencing platforms.
| Parameter | Illumina (NovaSeq X / 6000) | Element AVITI | PacBio (Revio / HiFi) | Oxford Nanopore (PromethION) |
|---|---|---|---|---|
| Technology | Sequencing by Synthesis (SBS) | Avidity Sequencing (SBA) | SMRT Sequencing (HiFi) | Nanopore current sensing |
| Typical Read Length | 2 × 150 bp (up to 2 × 300) | 2 × 150 bp | HiFi 10–20 kb (up to 25 kb) | Ultra-long (N50 20–50+ kb, up to Mb) |
| Raw Base Accuracy | >99.9% (Q30 > 85–92%) | Very High (often Q40 claims) | ~85–90% raw → HiFi >99.9% | ~Q20–Q25 (latest chemistry) |
| Consensus / HiFi Accuracy | >99.99% | >99.99% | >99.9% (Q30+) | Up to Q40+ (50× consensus) |
| Max Throughput (per run) | Up to 16 Tb (NovaSeq X Plus) | High (competitive mid-high) | ~120 Gb per SMRT Cell (Revio) | Up to 1–2+ Tb per PromethION flow cell |
| Best Strength | High-throughput, mature ecosystem, clinical validation | High accuracy + cost efficiency | Highest accuracy long reads | Ultra-long reads + real-time + methylation |
| Relative Cost per Gb | Lowest for very large projects | Very competitive | Higher | Competitive for long-read |
| Structural Variant (SV) Detection | Moderate (needs special callers) | Moderate | Excellent | Excellent |
| De novo Assembly | Good with short-read assemblers | Good | Excellent | Excellent (especially hybrid) |
| Clinical / Diagnostic Use | Most mature & widely validated | Growing | Growing | Growing (real-time advantage) |
| Real-time Sequencing | No | No | No | Yes |
| Native Methylation Detection | No | No | Yes | Yes (direct) |
Other Relevant Technical Considerations
- Library Preparation & Input DNA • Illumina & AVITI: Generally lower input, robust PCR-free options. • PacBio: Requires high-molecular-weight DNA, more careful handling. • Nanopore: Very flexible input (including ultra-low input and native DNA/RNA).
- Bioinformatics & Data Analysis • Short-read (Illumina/AVITI): Mature pipelines (BWA-MEM, GATK, DRAGEN). • Long-read: minimap2, flye, hifiasm, verkko, Canu + polishing with short reads. • Yaazh Xenomics provides end-to-end analysis on all platforms, including hybrid assembly and clinical-grade reporting.
- Clinical vs Research Use • Illumina remains the most clinically validated platform globally. • PacBio and Nanopore are increasingly used in clinical research and are gaining regulatory traction. • We help you choose based on intended use (research publication vs diagnostic reporting).
Our Recommendation at Yaazh Xenomics
Platform Agnostic: We do not push one platform. We match the technology to your biological question:
Clinical & Population: Large-scale clinical WES/WGS or population genomics → Illumina (primary) or AVITI
Rare Disease: Rare disease diagnostics with suspected structural variants → PacBio HiFi or Nanopore + Illumina hybrid
Metagenomics & Methylation: Rapid pathogen/metagenomics or methylation studies → Nanopore
Complex Genomes: Highest-quality de novo or complex genome assembly → PacBio or Nanopore hybrid